These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22773078)

  • 1. [Estimation of the execution of the national strategy of leprosy elimination in the "Hauts Bassins" region in Burkina Faso].
    Diallo B; Barro Traoré F; Andonaba JB; Tapsoba P; Sawadogo G; Traoré A
    Mali Med; 2012; 27(1):27-32. PubMed ID: 22773078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the elimination of leprosy in Burkina Faso].
    Tiendrebeogo A; Sow SO; Sawadogo O; Dembele MS; Ouedraogo K; Bide L; Millan J
    Acta Leprol; 1998; 11(1):7-16. PubMed ID: 9693686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in detection of new leprosy cases at two centres in Himachal Pradesh, India: a ten-year study.
    Mahajan VK; Sharma NL; Rana P; Sood N
    Indian J Lepr; 2003; 75(1):17-24. PubMed ID: 15253391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
    Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
    Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):371-8. PubMed ID: 10700910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLEP--current situation and strategy during the 11th plan period (2007-2012).
    Dhillon GP
    J Indian Med Assoc; 2006 Dec; 104(12):671-2. PubMed ID: 17474280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapses in multibacillary leprosy patients after multidrug therapy.
    Poojabylaiah M; Marne RB; Varikkodan R; Bala N; Dandakeri S; Martis J
    Lepr Rev; 2008 Sep; 79(3):320-4. PubMed ID: 19009982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The national leprosy eradication programme in India.
    Mittal BN
    World Health Stat Q; 1991; 44(1):23-9. PubMed ID: 2068822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Survey of leprosy disabilities in patients treated with multiple drug therapy in Ivory Coast].
    Tiendrebéogo A; Djakeaux DS; Assé H; Eba ME; Sica A
    Acta Leprol; 1997; 10(3):151-8. PubMed ID: 9281294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of lot quality assurance sampling for leprosy elimination monitoring--examination of some critical factors.
    Gupte MD; Murthy BN; Mahmood K; Meeralakshmi S; Nagaraju B; Prabhakaran R
    Int J Epidemiol; 2004 Apr; 33(2):344-8. PubMed ID: 15082637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case finding survey for leprosy in Botswana.
    Kumaresan JA; Khulumani P; Maganu ET
    East Afr Med J; 1993 Oct; 70(10):635-8. PubMed ID: 8187660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of national leprosy eradication programme in Satara District, Maharashtra.
    Mohite RV; Durgawale PM
    Indian J Lepr; 2011; 83(3):139-43. PubMed ID: 22443076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood leprosy in Essimbiland of Cameroon: results of chart review and school survey.
    Nsagha DS; Bamgboye EA; Oyediran AB
    Nig Q J Hosp Med; 2009; 19(4):214-9. PubMed ID: 20836334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiological survey of leprosy conducted in metropolitan France between 2009 and 2010].
    Bret S; Flageul B; Girault PY; Lightburne E; Morand JJ
    Ann Dermatol Venereol; 2013 May; 140(5):347-52. PubMed ID: 23663706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leprosy in Lome, Togo: retrospective study of 383 cases].
    Saka B; Kombate K; Mouhari-Toure A; Amegan-Aho KH; Tchangai-Walla K; Pitche P
    Med Trop (Mars); 2008 Oct; 68(5):496-8. PubMed ID: 19068982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and treatment outcomes of leprosy patients detected during a leprosy elimination campaign in Mozambique compared with routinely detected patients.
    Phaff C; Van Den Broek J; MacArthur A; Ndeve A; Stuip Y
    Lepr Rev; 2003 Sep; 74(3):229-39. PubMed ID: 14577468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy.
    Daniel E; Rao PS; Ffytche TJ; Courtright P
    Indian J Lepr; 2010; 82(4):181-8. PubMed ID: 21434594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.